StatSure Diagnostic Systems (SSUR)

[BonelessCat]

NEWS: StatSure Awarded Patents in Japan and India
Tuesday November 27, 8:30 am ET


FRAMINGHAM, Mass., Nov. 27 /PRNewswire-FirstCall/ -- StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR - News) announced the issuance in Japan and in India of additional international patents for its diagnostic testing platform, termed the "barrel" technology. StatSure's technology is also protected by a US patent and is part of a licensed, FDA approved and CLIA waived product for HIV, currently being sold in the US and elsewhere. The barrel technology is an integrated, disposable device used to rapidly and safely collect, process and test patients in point-of care locations to screen for certain infectious diseases. Results can be read within minutes, without instrumentation and the kit may be stored without refrigeration for up to 24 months. Point-of- care markets include clinics, doctors' office, emergency rooms and many other sites where results are needed quickly and safely.

The barrel-based product requires a tiny drop (~2.5 microliters) of whole blood, serum, or plasma and eliminates the need to separately handle, collect, and dispense a physiological specimen. Typically, the tip of the barrel touches a drop of fingertip blood, and though capillary action moves the specimen to the test strip inside the barrel, thereby minimizing the possibility of technician exposure to the potentially infected blood. A buffer vial sits atop the barrel forming a full kit with no other items needed. The test comes with an internal control to confirm that the test has been done correctly.